Dabigatran’s safety and efficacy established for management of VTE in children


INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.1,2 The data showed dabigatran to be as effective and have a comparable safety profile to the current standard of care (SOC) for the treatment of acute venous thromboembolism (VTE) in children.1 A favourable safety profile for dabigatran w http://www.businesswire.com/news/home/20190708005687/en/Dabigatran%E2%80%99s-safety-efficacy-established-management-VTE-children/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==